CBIO (Crescent Biopharma) Beneish M-Score


CBIO Crescent Biopharma Inc CBIO
10 GF Score
Price $18.56
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Beneish M-Score?

Crescent Biopharma does not have enough data to calculate Beneish M-Score.

Crescent Biopharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Beneish M-Score Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Beneish M-Score
0.00 0.00

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

CBIO vs RIGL, GYRE, TRAX: Beneish M-Score Comparison

For the Biotechnology subindustry, Crescent Biopharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's Beneish M-Score falls into.


CBIO
10GF Score
Crescent Biopharma Inc CBIO
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Business Description

Other Exchanges C68:Germany
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for CBIO

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price